

**Policy Recommendation: Faecal Microbiota Transplants**

**Date of Issue:** February 2017

The Priorities Committee has reviewed the evidence of clinical and cost effectiveness of Faecal microbiota transplants and recommends:

- Commissioning FMT for recurrent or refractory *C. difficile* infection up to a maximum of two transplants. FMT for any other indication is not routinely funded.

**Supporting Information**

- The majority of the weight of evidence presented has been provided from activities and positive national endorsement from both Public Health England and NICE Interventional Procedure Guidance.
- Realistic cost of £600 per patient based on the Department of Health guidance, including the cost of screening, hospital admission, x-ray, NGA tube, laxatives and vancomycin.
- There is interest in the use of FMT for the treatment of other disorders. FMT is already recognised as an emerging treatment for recurrent *Clostridium difficile* infections in patients where antibiotic and other lines of treatment have failed, and the role of the intestinal microbiota is recognised as being involved in the pathogenesis of inflammatory bowel disease.

*Notes:*

***Whilst the panel recognised the considered expert advice of NICE in their recommendation the panel also had a duty to prioritise spending of a finite resource locally and made a decision which it felt gave the most equitable and effective use of investment.***